Photo of Richard T. Maziarz, MD

Richard T. Maziarz MD

Dr. Maziarz specializes in treating bone marrow transplantation and blood cancers. His research interests cover how the immune system recovers after a bone marrow transplant and how the immune system works to fight cancer. Dr. Maziarz sees patients with leukemia, lymphoma and graft vs. host disease and patients who are being treated with immune system therapies.

Education

  • M.D., Harvard Medical School, 0 0 1979
  • Residency:

    • University Hospitals of Cleveland, 1981
  • Fellowship:

    • Immunology, Dana-Farber Cancer Institute, 1985
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 1982

Memberships and associations

  • American Society of Hematology

Publications

  • "Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia." Biology of Blood and Marrow Transplantation  In: , Vol. 23, No. 5, 01.05.2017, p. 767-775.
  • "Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes." Journal of Clinical Oncology In: , Vol. 35, No. 11, 10.04.2017, p. 1154-1161.
  • "Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies : A CIBMTR study." Bone Marrow Transplantation In: , Vol. 52, No. 2, 01.02.2017, p. 270-278.
  • "Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation : Long-term Follow-up of a Randomized Clinical Trial." JAMA oncology  In: , Vol. 2, No. 12, 01.12.2016, p. 1583-1589.
  • "The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes." Haematologica  In: , Vol. 101, No. 11, 31.10.2016, p. 1426-1433.
  • "Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma : A CIBMTR Analysis." Biology of Blood and Marrow Transplantation  In: , Vol. 22, No. 10, 01.10.2016, p. 1893-1899.
  • "Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes." Bone Marrow Transplantation In: , 12.09.2016.
  • "Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome." Journal of Clinical Oncology  In: , Vol. 34, No. 16, 01.06.2016, p. 1864-1871.
  • "Mesenchymal stromal cells : Potential roles in graft-versus-host disease prophylaxis and treatment." Transfusion In: , Vol. 56, No. 4, 01.04.2016, p. 9S-14S.
  • "Erratum : Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: A CIBMTR infection and immune reconstitution analysis (Bone Marrow Transplantation (2016) 51 (277-282) DOI:10.1038/bmt.2015.263)." Bone Marrow Transplantation In: , Vol. 51, No. 2, 01.02.2016, p. 322.
  • "Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT : A CIBMTR infection and immune reconstitution analysis." Bone Marrow Transplantation In: , Vol. 51, No. 2, 01.02.2016, p. 277-282.
  • "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia : A CIBMTR Cohort Analysis." Biology of Blood and Marrow Transplantation  In: , 22.12.2015.
  • "Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia." Biology of Blood and Marrow Transplantation  In: , 16.12.2015.
  • "Solution-phase crosstalk and regulatory interactions between multipotent adult progenitor cells and peripheral blood mononuclear cells." Stem cells translational medicine In: , Vol. 4, No. 12, 01.12.2015, p. 1436-1449.
  • "Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease." British Journal of Haematology In: , Vol. 171, No. 3, 01.11.2015, p. 411-416.
  • "Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning." Cancer In: , Vol. 121, No. 20, 01.10.2015, p. 3709-3716.
  • "Chronic GvHD-associated serositis and pericarditis." Bone Marrow Transplantation In: , Vol. 50, No. 8, 08.08.2015, p. 1098-1104.
  • "Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation." British Journal of Haematology In: , Vol. 170, No. 4, 01.08.2015, p. 574-583.
  • "Single and multiple dose multistem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation : A phase 1 trial." Biology of Blood and Marrow Transplantation In: , Vol. 21, No. 4, 01.04.2015, p. 720-728.
  • "Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation." Biology of Blood and Marrow Transplantation  In: , Vol. 21, No. 3, 01.03.2015, p. 552-558.
  • "Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes." Biology of Blood and Marrow Transplantation In: , Vol. 21, No. 1, 01.01.2015, p. 151-158.
  • "Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population." Biology of Blood and Marrow Transplantation In: , Vol. 21, No. 1, 01.01.2015, p. 89-96.
  • "Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy." Biology of Blood and Marrow Transplantation In: , Vol. 21, No. 1, 01.01.2015, p. 55-59.
  • "Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome." Bone Marrow Transplantation In: , Vol. 49, No. 11, 13.11.2014, p. 1360-1365.
  • "Optimal benefits for hematopoietic stem cell transplantation : A consensus opinion." Biology of Blood and Marrow Transplantation In: , Vol. 20, No. 11, 01.11.2014, p. 1671-1676.
  • "Comorbidity-age index : A clinical measure of biologic age before allogeneic hematopoietic cell transplantation." Journal of Clinical Oncology In: , Vol. 32, No. 29, 10.10.2014, p. 3249-3256.
  • "Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation : A single institution retrospective study." Clinical Lymphoma, Myeloma and Leukemia In: , Vol. 14, No. 5, 01.10.2014, p. 424-430.e1.
  • "Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality." Blood In: , Vol. 124, No. 2, 10.07.2014, p. 287-295.
  • "Translin/TRAX deficiency affects mesenchymal differentiation programs and induces bone marrow failure."   Stem Cells and Human Diseases. Springer Netherlands, 2014. p. 467-484.
  • "Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma." Leukemia and Lymphoma In: , Vol. 55, No. 3, 03.2014, p. 583-587.

Additional information

Edit profile